Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

The Lancet

Volumn 375, Issue 9727, 2010, Pages 1695-1703

  Lees, Kennedy R ^a   Bluhmki, Erich ^b   von Kummer, Rüdiger ^c   Brott, Thomas G ^d   Toni, Danilo ^e   Grotta, James C ^f   Albers, Gregory W ^g   Kaste, Markku ^h   Marler, John R ⁱ   Hamilton, Scott A ^g   Tilley, Barbara C ^j   Davis, Stephen M ^k   Donnan, Geoffrey A ^k   Hacke, Werner ^l  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d MAYO CLINIC   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g STANFORD UNIVERSITY   (United States)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK BENEFIT ANALYSIS; STROKE; TREATMENT DURATION;

EID: 77952112006     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60491-6     Document Type: Article

References (29)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
2. Hacke W., Kaste M., Bluhmki E., et al., for the European Cooperative Acute Stroke Study (ECASS) investigators. Alteplase compared with placebo within 3 to 4·5 hours for acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
3. Hacke W., Kaste M., Fieschi C., et al., for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
4. Hacke W., Kaste M., Fieschi C., et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352 (1998) 1245-1251
5. Clark W.M., Albers G.W., Madden K.P., Hamilton S., and for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a double-blind, placebo-controlled, multicenter study. Stroke 31 (2000) 811-816
6. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study-a randomized controlled trial. JAMA 282 (1999) 2019-2026
7. Davis S.M., Donnan G.A., Parsons M.W., et al., for the EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7 (2008) 299-309
8. The A., ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
9. Wahlgren N., Ahmed N., Dávalos A., et al., for the SITS investigators. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372 (2008) 1303-1309
10. Haley Jr. E.C., Brott T.G., Sheppard G.L., et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 24 (1993) 1000-1004
11. Brott T., Adams H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20 (1989) 864-870
12. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke 16 (1995) 885-890
13. Van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J., and van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988) 604-607
14. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel Index. Md State Med J 14 (1965) 61-65
15. Wahlgren N., Ahmed N., Dávalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
16. Lees K.R., Zivin J.A., Ashwood T., et al. NXY-059 for acute ischemic stroke. N Engl J Med 354 (2006) 588-600
17. Chi G. Multiple testing: multiple comparisons and multiple endpoints. Drug Inf J 32 (1998) 1347S-1362S
18. Marler J.R., Tilley B.C., Lu M., et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 55 (2000) 1649-1655
19. Saver J.L., Gornbein J., Grotta J., et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4·5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 40 (2009) 2433-2437
20. Von Kummer R. After European Cooperative Acute Stroke Study 3: mission accomplished?. Stroke 40 (2009) 2268-2270
21. Lapchak P.A., Chapman D.F., and Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31 (2000) 3034-3040
22. Hacke W., Furlan A.J., Al-Rawi Y., et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 8 (2009) 141-150
23. Köhrmann M., and Schellinger P. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. Radiology 251 (2009) 627-633
24. Wintermark M., Rowley H.A., and Lev M.H. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro CT. Radiology 251 (2009) 619-626
25. Alexandrov A.V., Molina C.A., Grotta J.C., et al., for the CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 (2004) 2170-2178
26. Pancioli A.M., Broderick J., Brott T., et al., for the CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 39 (2008) 3268-3276
27. Sugg R.M., Pary J.K., Uchino K., et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 63 (2006) 1057-1062
28. Khatri P., Hill M.D., Palesch Y.Y., et al., for the Interventional Management of Stroke III Investigators. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 3 (2008) 130-137
29. Saver J.L., Kidwell C., Eckstein M., Starkman S., and for the FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 35 (2004) e106-e108